The Hypoglycemic Drugs Market is estimated to be valued at US$ 720.72 Mn in 2023 and is expected to exhibit a CAGR of 9.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

The Hypoglycemic Drugs Market is witnessing high growth owing to increasing prevalence of diabetes. Diabetes is a chronic disease that occurs when blood glucose level is high due to insulin deficiency or when body fail to use glucose properly. The Global Burden of Disease (GBD) 2019 Study estimates that worldwide prevalence of diabetes has nearly quadrupled since 1980, rising from 108 million to 422 million today.

Market Overview:
Hypoglycemic drugs are used to treat high blood sugar levels or hyperglycemia in diabetes patients. The commonly used hypoglycemic drugs include insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists. Insulin is the most effective therapy for controlling blood sugar levels in diabetes patients. Biguanides and sulfonylureas are commonly prescribed oral hypoglycemic drugs.

Market key trends:
One of the major trend in the hypoglycemic drugs market is the rising adoption of combination therapy. Combining two or more medications that work through different mechanisms offers the potential for controlling blood sugar levels more effectively. For instance, combining metformin with a DPP-4 inhibitor or GLP-1 receptor agonist is increasingly being used to manage type 2 diabetes. Combining medications can help control blood sugar levels while minimizing side effects through use of lower doses of each component. This approach has gained widespread acceptance from healthcare professionals and patients alike. The combination therapies segment of the market is expected to witness high growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is relatively low due to high capital requirements for R&D and manufacturing. The hypoglycemic drugs market is dominated by major pharmaceutical companies with established brand names.

Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of generic alternatives. However, branded hypoglycemic drugs continue to dominate the market due to strong brand loyalty.

Bargaining power of suppliers: The bargaining power of suppliers is moderate given the availability of raw material substitutes and suppliers. However, key active pharmaceutical ingredients used in hypoglycemic drugs have few or limited suppliers.

Threat of new substitutes: The threat of new substitutes is moderate as several new drug delivery methods and newer drug classes are being researched. However, existing drugs have strong brand recognition and patient adherence.

Competitive rivalry: High due to presence of numerous international and regional players competing on basis of product differentiation, branding and marketing.

SWOT Analysis

Strengths: Established brand names, global presence of major players, wide product portfolio and pipeline drugs.

Weaknesses: High R&D costs, pricing pressures from generic alternatives, patent cliffs on blockbuster drugs.

Opportunities: Expanding patient pool, emerging markets growth, new drug delivery methods and newer drug classes.

Threats: Patent expiries of major drugs, price control regulations, unfavorable drug replacement policies.


Key Takeaways

The global Hypoglycemic Drugs Market Growth  is expected to witness high growth, exhibiting CAGR of 9.2% over the forecast period, due to increasing prevalence of diabetes globally. According to the International Diabetes Federation, around 643 million people aged 20-79 years are projected to have diabetes by 2030.

Regionally, North America dominates the hypoglycemic drugs market currently due to high diabetes incidences and availability of advanced treatment options. However, Asia Pacific is expected to witness the highest growth rate during the forecast period owing to rising diabetes prevalence, growing healthcare expenditure and increasing focus of international players.

Key players operating in the Hypoglycemic Drugs market are Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceutica NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG., Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd. Major companies are focusing on new product launches, expansion into high growth markets and acquisitions to strengthen their market position.

Read More,

https://www.newsstatix.com/hypoglycemic-drugs-market-trends-size-and-share-analysis/